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Abstract
Background: To develop a screening algorithm to detect hepatic steatosis in overweight and obese adolescents.
Methods: We performed a cross sectional study of 129 overweight adolescents 13–18 yrs. The primary outcome,
hepatic steatosis was defined as an intracellular triglyceride content > 5.5 mg/g and quantified using 1H-magenetic
resonance spectroscopy. Primary predictor variables included, alanine and aspartate transaminases (ALT/AST) and
features of the metabolic syndrome.
Results: Hepatic steatosis was present in 33 % of overweight and obese adolescents. Adolescents with hepatic
steatosis were more likely to be boys (adjusted OR: 4.8; 95 % CI: 2.5–10.5), display a higher waist circumference (111 ±
12 vs 100 ± 13 cm, p < 0.001) and have metabolic syndrome (adjusted OR: 5.1; 95 % CI: 1.6–16.4). Serum ALT predicted
hepatic steatosis in boys (AUC: 0.82; 95 % CI: 0.70–0.95; p < 0.001) but not girls (AUC = 0.63; 95 % CI: 0.46–0.75, p = 0.16).
An ALT >20 U/L, combined with the presence of metabolic syndrome, male gender and an elevated waist
circumference provided the best model (AUC 0.85) with high sensitivity (72 %) and specificity (82 %) and positive and
negative predictive values of 61 % and 89 % respectively.
Conclusions: Serum transaminases provide modest predictive value for hepatic steatosis in youth. The ALT threshold
for predicting hepatic steatosis is significantly lower than current clinical thresholds for predicting non-alcoholic fatty
liver disease. The addition of ALT, presence of the metabolic syndrome and male gender significant improve the ability
to predict hepatic steatosis.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of liver disease in children [1]. The
prevalence of NAFLD has increased in parallel with the
rise in childhood obesity [2]. NAFLD is a spectrum
term that includes several stages of liver disease includ-
ing the earliest stage of simple hepatic steatosis, the
more severe non-alcoholic steatohepatitis and precedes
the advanced stage of cirrhosis [3]. Population- and
clinic-based studies suggest that 25–47 % of overweight
and obese youth display some form of liver disease along
the spectrum of NAFLD [2, 4, 5]. The clinical diagnosis of
NAFLD relies initially on the detection of elevated serum
transaminases followed by confirmation with hepatic ultra-
sound and finally a liver biopsy to score the degree of cellu-
lar damage, inflammation and fatty infiltration [3, 6, 7].
Current guidelines recommend the use of alanine amino-
transferase (ALT) to initially screen for NAFLD in obese
youth within community practice settings [8]. However,
the appropriate ALT value for detecting hepatic steato-
sis, the earliest stage in the natural history of NAFLD,
is unknown and current clinical thresholds significantly
exceed the upper limit of normal for metabolically
healthy youth [9].
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The lack of consensus regarding the appropriate serum
transaminase thresholds to detect hepatic steatosis is re-
lated, in part, to the scarcity of studies that measure hep-
atic triglyceride directly. The Screening ALT for Elevation
in Today’s Youth (SAFETY) study recently reported that
among otherwise healthy children, the 95th percentile for
ALT is ~26 U/L for boys and ~23U/L for girls, suggesting
much lower ALT thresholds should be used to initially
screen for chronic liver disease in children [9]. Thresholds
based on the 95th percentile provided high sensitivity and
specificity for the detection of biopsy-proven NAFLD in
obese adolescents [9]. Unfortunately, the study failed to
identify serum transaminase thresholds for adolescents
with hepatic steatosis alone, prior to the progression to
the more extreme non-alcoholic steatohepatitis (NASH)
[4, 10]. Identifying overweight youth in the earliest stages
of fatty liver disease may be important for the early detec-
tion and prevention of progression to NAFLD or other
associated metabolic disorders [4, 10–12].
In an effort to overcome these limitations, we performed
a cross sectional study of [1] H-magnetic resonance
spectroscopy-derived measures of hepatic triglyceride
content and serum measures of liver transaminases in a
sample of overweight and obese adolescents enrolled in a
therapeutic trial to reduce hepatic triglyceride content.
We hypothesised that the ALT thresholds with the best
sensitivity and specificity for detecting hepatic steatosis in
overweight and obese youth would be lower than current
clinical cut-points. A secondary aim was to develop an al-
gorithm using commonly measured metabolic risk factors
to predict hepatic steatosis that would be useful in a com-
munity pediatric outpatient setting.
Research design and methods
Study design and study population
Between 2008 and 2012, 181 youth aged 13–19 years were
screened for participation in a randomized controlled trial
of physical activity on risk factors associated with the
development type 2 diabetes (www.clinicaltrials.gov;
NCT00755547). Of the 181 adolescents screened, 129
were overweight or obese and provided valid measures of
hepatic triglyceride content as well as measures of serum
liver transaminases, cholesterol, blood pressure and waist
circumference and were included in this cross sectional
study [4, 10]. Participants were classified as overweight or
obese according to age- and sex-specific BMI cut points
established by the International Obesity Task Force [13].
All participants were screened with a 75 g 2-hr oral glu-
cose tolerance test and those with a diagnosis of type 2
diabetes or impaired glucose tolerance were excluded. We
also excluded adolescents (1) treated with antipsychotics,
hepatotoxic medications or corticosteroids, (2) with infec-
tious causes of hepatitis, (3) reporting frequent binge
drinking; (4) other self-reported concomitant liver diseases
or (5) enrolment in a weight loss program in the 6 months
prior to their first study visit. Adolescents who were un-
able to undergo MRI due to weight or size restrictions
were also excluded. Among the 52 adolescents that failed
to meet inclusion criteria, 29 were excluded because of
impaired glucose tolerance or type 2 diabetes during the
initial screening phase, 8 did not have a measure of
hepatic triglyceride content and 15 were not overweight
or obese. All participants and parents provided written
informed consent for observational studies of tissue
steatosis and insulin resistance in youth as well as partici-
pation in the randomized controlled trial (NCT00755547).
The study was approved by the University of Manitoba
Biomedical Research Ethics Board (B2006:091) and the
National Research Council of Canada (W2007-04) in ac-
cordance with the Declaration of Helsinki.
Primary outcome measure: hepatic steatosis
Hepatic triglyceride content was quantified using mag-
netic resonance spectroscopy on a 1.5 or 3.0 T whole
body magnet (GE Medical Systems, Milwaukee, WI)
[4, 10, 14, 15]. Using MRI-derived high resolution im-
ages, a single voxel (40 mm3) was prescribed within
the upper right lobe of the liver in an area devoid of
subcutaneous or visceral fat as to prevent unwanted
lipid contamination from peripheral tissue. To further
prevent peripheral lipid contamination, several spatial
saturation bands which act to null peripheral lipid signals
were manually placed around the voxel. Using the PRESS
based localization sequence, with TE = 25 ms and TR =
3 s, we acquired a total of 64 spectra and 1,024 data points
over a 1,000-Hz spectral width. LCModel software was
used to isolate and quantify lipid and water peaks [4, 10,
16]. Hepatic steatosis was defined as hepatic triglyceride
content of >5.5 % fat/water based on previous population-
based studies and the observation that it is equivalent to a
biopsy-derived lipid concentration of 5.5 mg/g [3, 15].
Predictor variables
Serum alanine (ALT) and aspartate transaminase levels
(AST) were treated as continuous variables and measured
on a Roche Modular P Analyze after a 10-hr overnight
fast. Metabolic syndrome was treated as a binary outcome
measure using cut points for systolic blood pressure,
serum triglycerides, waist circumference, fasting glucose,
and HDL- cholesterol (HDL-C) that were statistically de-
rived to reflect cut points in adults [17]. Adolescents were
described as having metabolic syndrome if they had three
or more of five comorbidities [17]. Resting systolic and
diastolic blood pressure were measured in triplicate in a
sitting position using a Dinamap automatic machine, as
recommended by the National Committee on Preventive,
Detection, Evaluation and Treatment of High Blood
Pressure [18]. Plasma glucose was measured on a Roche
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Modular P analyzer using the hexokinase method. LDL
cholesterol (LDL-C) was calculated using the Friedewald
equation (LDL-C = total cholesterol − [HDL-C − (trigly-
ceride/2.2)]) [10]. Insulin was measured on an Immulite
chemiluminescent immunometric assay. HOMA-IR was
calculated using a standard formula [19]. Ethnicity was
self-reported by parents and/or adolescents.
Body weight was measured to the nearest 0.1 kg on a
calibrated scale. Height was obtained with a standard
stadiometer and measured to the nearest 0.5 cm. Abso-
lute body mass index (kg/m2) was converted to a BMI
Z-score using nationally representative age and sex
specific normative data using EpiInfo software [20].
Dual-energy X-ray absorptiometry (Hologic, Bedford,
MA) was used to quantify percent body fat, total fat
mass and fat free mass.
Statistical analysis
Descriptive data are presented as mean ± SD or propor-
tions where appropriate. Differences in demographic
variables between youth with and without hepatic steato-
sis were performed using independent T-tests or Mann
Whitney U tests where appropriate. The primary out-
come for all regression analyses and receiver operating
curves was hepatic steatosis, treated as a binary outcome
(>5.5 % fat/water). Univariate analyses between predictor
variables and hepatic steatosis were performed using
Kruskal-Wallis and chi-square analyses as appropriate.
Area under the curve (AUC), sensitivity, specificity, and
positive- and negative-predictive values for the use of
ALT for predicting hepatic steatosis were calculated
from univariate logistic regression models, both for the
combined sample and separately by gender. Youden’s J
Statistic was used to determine the optimum cut-off
value for ALT to predict the presence of hepatic steato-
sis. Based on the results of a univariate analysis, six var-
iables were identified and entered into a multiple linear
regression for predicting hepatic steatosis. BMI Z Score,
ethnicity, metabolic syndrome, sex, waist circumference
and ALT were entered into the model to estimate AUC as
well as parameter estimates. A second multivariate model
with ALT dichotomized at 20 was fit as it was determined
to be the optimal cut-point to predict hepatic steatosis,
based on the results of unadjusted receiver operating
curves for predicting hepatic steatosis. Non-significant pa-
rameters were then removed, producing the final model.
All analyses were performed with SAS Version 9.3 (SAS
Institute, Cary NC).
Results
Participant demographics stratified according to the
presence of hepatic steatosis are provided in Table 1.
Among the 129 youth studied, 33 % (n = 42) displayed
hepatic steatosis. Compared to youth without hepatic
steatosis, those with steatosis were more likely to be
boys (OR: 4.8; 95 % CI: 2.5–10.5, p < 0.001), displayed a
higher BMI Z score, higher waist circumference and
were more likely to have the metabolic syndrome (OR:
6.7; 95 % CI: 3.0–15.2; p < 0.001). Youth with hepatic
steatosis displayed ALT values nearly 2-fold higher than
those without steatosis (p < 0.001), while AST values
were only marginally higher (26 vs 21 U/L, p = 0.02).
BMI Z score (AUC = 0.70; 95 % CI: 0.64–0.82, p–0.008)
and waist circumference (AUC = 0.73; 95 % CI: 0.61–0.80;
Table 1 Participant characteristics stratified by the presence of hepatic steatosis
Hepatic Steatosis (n = 43) No Hepatic Steatosis (n = 82) P-value
Female 24 64 <0.001
Age (yrs) 15 ± 2 15 ± 2 0.53
BMI (kg/m2) 33.8 ± 4.9 31 ± 4.5 0.002
BMI Z score 2.2 ± 0.4 1.9 ± 0.4 <0.001
Waist circumference (cm) 111 ± 12 100 ± 13 <0.001
Body fat percent (%) 38.9 ± 6.1 38 ± 5.9 0.43
Hepatic Triglyceride (%F/W) 13.0 ± 12.5 3.0 ± 1.2 <0.001
HOMA 6.4 ± 8.0 3.6 ± 3.2 0.43
HDL-cholesterol (mmol/L) 1.1 ± 0.3 1.2 ± 0.3 0.23
Triglycerides (mmol/L) 1.6 ± 0.7 1.1 ± 0.5 <0.001
AST (U/L) 26.4 ± 13.7 21.7 ± 8.8 0.008
ALT (U/L) 31.8 ± 22.8 19.0 ± 13.7 <0.001
Systolic BP (mmHg) 116 ± 12 114 ± 11 0.35
Diastolic BP (mmHg) 62 ± 8 65 ± 8 0.08
Metabolic syndrome 40 % 12 % <0.001
Data are means ± standard deviation unless otherwise stated. BMI Body mass index, HOMA-IR homeostatic model assessment- insulin resistance, HDL High density
lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, BP blood pressure
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p < 0.001) were both modest but significant predictors
of hepatic steatosis. AST (AUC: 0.65; 95 % CI: 0.55–
0.74, p = 0.008) provided poor predictive value for the
presence of hepatic steatosis (Fig. 1a). ALT (AUC: 0.74;
95 % CI: 0.64–0.83, p < 0.001) provided modest predict-
ive value for the presence of hepatic steatosis (Fig. 1b),
with an area under the curve similar to that provided
by BMI Z score and waist circumference. Sensitivity
and specificity for various ALT thresholds with corre-
sponding positive and negative predictive values are
presented in Table 2a. An ALT level of 20 U/L provided
the highest acceptable sensitivity (64.3 %) with the lowest
acceptable compromise in specificity (74.7 %). While
higher thresholds of ALT provided superior specificity,
rates of false negatives increased ~2-fold (18–30 %) and
the negative predictive value decreased from 82–71 %
(Table 2). As rates of hepatic steatosis were significantly
higher among boys, we also provided similar data across a
range of ALT values for boys alone (Table 2b). Due to the
low rates of steatosis in girls, a similar table was not pos-
sible to generate.
While ethnicity, and BMI Z score were associated with
hepatic steatosis in univariate models, they were not
significantly associated with hepatic steatosis among
overweight youth in the multivariate logistic regression
models (Table 3). The final multivariate logistic model
included the presence of metabolic syndrome (vs no
metabolic syndrome; aOR: 5.1; 95 % CI: 1.6–16.4); male
sex (aOR: 5.5; 95 % CI: 1.9–16.2), an ALT > 20 U/L
(aOR: 3.1; 95 % CI: 1.5–9.4) and waist circumference
(aOR: 1.06; 95 % CI: 1.02–1.10) (Table 4). The presence
of one or two individual components of the metabolic
syndrome were not associated with hepatic steatosis in
this cohort, suggesting that the presence of a minimum
of three risk factors is needed to predict of hepatic
steatosis in overweight/obese adolescents. Receiver op-
erating characteristic curves that combined all four cri-
teria yielded an AUC of 0.85 (p = 0.001) (Fig. 2b) with
high levels of sensitivity (0.72) and specificity (0.82).
A significant interaction between ALT and sex was
noted in preliminary analyses, therefore regression
models were constructed for boys and girls separately.
Among boys, the combination of presence of the meta-
bolic syndrome and ALT > 20 U/L provided an area
under the curve of 0.90 (95 % CI: 0.82–0.99). Among
girls, the presence of the metabolic syndrome and an
ALT > 20 U/L yielded an area under the curve of 0.74
(95 % CI: 0.58–0.89).
Discussion
To the best of our knowledge, this is the first diagnostic
study designed to identify a threshold for liver transam-
inases that predicts objectively measured hepatic steatosis
using magnetic resonance spectroscopy in overweight/
obese adolescents. The data build on the extensive work
of Nobili and colleagues [1, 21–24] and others [9], by
demonstrating that the threshold for ALT with the best
balance of positive and negative predictive value is much
lower than current clinical standards. Furthermore, the
findings presented here extend previous studies of over-
weight and obese youth [9, 23], by providing a novel
algorithm that detects hepatic steatosis.
Hepatic steatosis is one of the most common compli-
cations of obesity in children and adolescents [1, 3] and
a challenge for general pediatricians to detect and treat
[21]. Within the pediatric clinical settings, liver transam-
inases are used to initially screen for the presence of
fatty liver disease [10, 18], however recent studies sug-
gest a simple measure of transaminases in not sufficient
to detect hepatic steatosis or NAFLD [25]. Non-invasive
Fig. 1 Receiver operating characteristic curves for predicting hepatic steatosis with serum transaminase values. a = Aspartate transaminase (AST);
b = Alanine transaminase (ALT)
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imaging tools, such as magnetic imaging and ultrasound,
provide semi-quantitative insight into the degree of stea-
tosis [26–28], however are not generally used in general
pediatric settings. The threshold at which youth are con-
sidered “at risk” of NAFLD varies widely across settings
(30 – 66 U/L or “two-fold higher than normal”) due in
large part to the reliance on local measures of the upper
limits of normal [1, 9]. The SAFETY study recently
determined that (1) cut-off values are set too high for
reliable detection of pediatric chronic liver disease (In
fact, hepatic steatosis was detectable at ALT values 10–
50 % lower than conventional thresholds (25 U/L vs 30–
66 U/L)) and (2) that these lower cut points are sensitive
and specific to detecting liver diseases, including NAFLD,
in children and adolescents [9]. The data presented here
support the notion that the current clinical thresholds are
too high for detecting magnetic resonance spectroscopy-
derived hepatic steatosis as the number of false negatives
was ~2-fold higher using commonly used threshold (30 vs
18 %), compared to the lower threshold identified here.
The data also reinforce the limited utility of ALT alone as
a screening tool for hepatic steatosis in overweight/obese
adolescents, as the area under the curve was similar to
that for measures of adiposity. These data support the call
from others that the thresholds for detecting fatty liver
disease in children and adolescents need to be revised and
harmonized across pediatric clinical settings.
Table 2 a ALT threshold levels used in screening for hepatic steatosis and corresponding sensitivities and specificities for all participants
ALT (U/L) Sensitivity Specificity Positive predictive value Negative predictive value
>20 64 % 77 % 57 % 82 %
>25 48 % 86 % 62 % 77 %
>30 33 % 90 % 61 % 74 %
>35 24 % 92 % 59 % 71 %
>40 19 % 94 % 62 % 71 %
>66 U/L 10 % 99 % 75 % 71 %
b
ALT threshold levels used in screening for hepatic steatosis and corresponding sensitivities and specificities for boys only
ALT (U/L) Sensitivity Specificity Positive predictive value Negative predictive value
>20 79 % 63 % 73 % 71 %
>25 66 % 78 % 80 % 65 %
>30 45 % 89 % 85 % 57 %
>35 38 % 89 % 82 % 53 %
>40 29 % 95 % 88 % 51 %
>66 U/L 20 % 100 % 100 % 50 %
Table 3 Predictors of hepatic steatosis in overweight and obese
adolescents
Point Estimate 95 % CI
BMI Z score 2.67 0.94–9.67
Indigenous vs Other 0.59 0.12–2.96
Caucasian vs Other 0.75 0.17–3.27
Metabolic Syndrome
Components
1 vs 0 0.95 0.14–6.50
2 vs 0 1.64 0.26–10.52
3 or 4 vs 0 6.54 0.87–49.05
Sex (M vs F) 3.61 1.31–9.93
AST (U/L) 3.14 1.22–8.09
Fig. 2 Receiver operating curve for the utility of the new algorithm
for predicting the presence of hepatic steatosis in overweight and
obese adolescents Results of a multiple regression analysis that included
ALT > 20 U/L, male sex, waist circumference and the presence of the
metabolic syndrome
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The metabolic syndrome consists of a clustering of
cardiometabolic risk factors that, in adults, is associated
with cardiovascular disease and type 2 diabetes [29, 30].
The metabolic syndrome in childhood is a strong pre-
dictor of impaired glucose tolerance and progression to
type 2 diabetes in adulthood [31]. Our group and others
have documented that hepatic steatosis is a robust pre-
dictor of metabolic syndrome and type 2 diabetes in
overweight and obese adolescents [1, 4, 10, 22, 24, 30]. It
is not surprising therefore, that adding the presence of 3
or more metabolic syndrome features to a measure of
ALT provides significantly greater predictive power for
detecting hepatic steatosis in overweight/obese adoles-
cents. Importantly, the presence of one or two individual
risk factors was not predictive of hepatic steatosis in ad-
olescents, reinforcing the notion that hepatic steatosis
and the metabolic syndrome are intimately linked. The
presence of visceral obesity is likely an important medi-
ator of this association as it is often associated with both
conditions [32] and the observation that waist circum-
ference was positively associated with hepatic steatosis
in this study, reinforces it's utility in the clinical assess-
ment of obese adolescents. From a clinical standpoint,
these data reinforce the concept that cardiometabolic
risk factors tend to cluster in overweight and obese
youth, which may be a harbinger of clinically relevant
cardiometabolic endpoints.
Sex differences exist in the partitioning of adipose tis-
sue in adults and youth [33]. The deposition of adipose
tissue in the visceral space is more common among boys
and men [33] and is generally highly correlated with the
presence of hepatic steatosis [34]. Biopsy studies support
these observations, demonstrating that NAFLD is more
common in overweight boys than girls [35]. The data
presented here support these studies and population-
based studies of hepatic steatosis using magnetic reson-
ance spectroscopy [15, 36, 37] as the presence of hepatic
steatosis was ~5-fold higher in boys compared to girls.
Based on the sex-based differences in the presence of
hepatic steatosis, the upper limits of normal for trans-
aminase levels are general higher for boys, relative to girls
[9, 14]. The ALT threshold we identified for the optimal
detection of hepatic steatosis in the current study was very
similar to the threshold used to detect biopsy-proven
NAFLD among boys [9] (20 vs 27 U/L). Interestingly, the
utility of ALT for predicting hepatic steatosis was poor
among overweight and obese girls, relative to boys (AUC
= 0.73 vs 0.90). This may reflect gender-specific conse-
quences of lipotoxicity on hepatocytes, or different thresh-
olds of intracellular triglyceride content at which liver
enzymes are released. Large population-based studies and
biopsy-based clinical investigations are needed to explore
the mechanisms for sex differences in the risk of hepatic
steatosis.
The current study expands on previous studies as we re-
lied on magnetic resonance spectroscopy to quantify hep-
atic triglyceride content in a relatively large community-
based sample of overweight and obese adolescents at a
presumable early stage of NAFLD. The study is also
strengthened by the use of predictor variables that are
commonly used in both hospital and community-based
pediatric care settings. Several limitations in the current
study design however, need to be addressed. As hepatic bi-
opsies were not performed on youth in this sample, it is
impossible to rule out the presence of NAFLD in those
with >5.5 % liver fat (i.e. hepatic steatosis) using single
voxel MR spectroscopy, potentially skewing the thresholds
for liver transaminases upwards. We feel this is unlikely to
have significantly influenced our results as none of the ad-
olescents self-reported a previous diagnosis of fatty liver
disease or elevated liver enzymes prior to their study visit.
Second, as this was a sample of youth recruited specifically
for a randomized trial of exercise training, selected based
on their risk for type 2 diabetes and the presence of low
levels of self-reported physical activity, the study is at risk
of selection bias and an overestimate of the prevalence of
hepatic steatosis. Third, while the new algorithm for pre-
dicting the presence of hepatic steatosis is superior to
using ALT alone, the sensitivity and specificity remain
sub-optimal, therefore a diagnosis of hepatic steatosis
should include imaging of the liver. Finally, as the study
was cross sectional, and lacked a validation cohort, these
findings need to be replicated and the time course of
changes in hepatic triglyceride content and the increase in
serum transaminase levels remains should be studied.
Despite these limitations, the data presented here provide
important initial insight into clinically-relevant predictors
of hepatic steatosis in overweight and obese youth.
Conclusions
The clinical thresholds for serum transaminases for de-
tecting hepatic steatosis in overweight and obese youth is
lower than the current recommended thresholds for iden-
tifying hepatic steatosis. The predictive value of ALT for
detecting hepatic steatosis is significantly greater among
overweight boys, than overweight girls. Finally, it is pos-
sible to predict the degree of hepatic steatosis with high
Table 4 Conventional variables used to predict hepatic steatosis
in obese adolescents
Point Estimate 95 % CI
MS 1 vs 0 1.05 0.16–7.05
MS 2 vs 0 2.09 0.33–13.26
MS 3 or 4 vs 0 8.34 1.16–60.0
Sex (M vs F) 4.40 1.64–11.83
AST (U/L) > 19 3.74 1.49–9.38
MS metabolic syndrome count, AST aspartate transaminase
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sensitivity using a serum measure of ALT, sex, waist cir-
cumference and the presence of the metabolic syndrome.
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